What is the main objective when using anticoagulation therapy in pregnant women?

The primary goal of anticoagulation therapy in pregnant women is to prevent thromboembolic complications during pregnancy. During pregnancy, there is an increased risk of thromboembolism due to physiological changes such as increased blood volume, alterations in coagulation factors, and reduced mobility. Anticoagulants help to reduce the risk of thrombotic events like deep vein thrombosis (DVT) and pulmonary embolism (PE), which can have serious consequences for both the mother and the fetus.

Enhancing fetal growth, promoting maternal sleep, and relieving nausea and vomiting are not direct objectives of anticoagulation therapy. These concerns may be addressed through other medications or interventions but are not related to the purpose of anticoagulation in the context of managing clotting risks during pregnancy. Thus, the focus of anticoagulation is specifically on maintaining maternal safety and preventing complications associated with blood clots.